QED THERAPEUTICS
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
QED THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.qedtx.com
Total Employee:
11+
Status:
Active
Contact:
1-877-280-5655
Email Addresses:
[email protected]
Total Funding:
65 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Wordpress Plugins Euro
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Current Employees Featured
Investors List
BridgeBio Pharma
BridgeBio Pharma investment in Venture Round - QED Therapeutics
Official Site Inspections
http://www.qedtx.com
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "QED Therapeutics"
QED Therapeutics - Crunchbase Company Profile & Funding
Organization. QED Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone …See details»
Responsibilities - qedtx.com
Commercial leadership team to help build the organization as it operates, scaling the company to provide excellent support. Job Responsibilities: ... Please submit your resume to …See details»
QED Therapeutics Company Profile | Management and Employees …
[email protected]: QED Therapeutics Top Competitors. Company Employees Revenue Top technologies; Inspyr Therapeutics Inc. 1: $212 K: X4 Pharmaceuticals Inc. 86: $28 M: …See details»
QED Therapeutics Overview | SignalHire Company Profile
Organization Website: qedtx.com : Social Links: Contact Email [email protected] Phone Number: 1-877-280-5655: QED Therapeutics industries Biotech: Headquarters Location: 421 Kipling …See details»
QED Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Www.qedtx.com. Startups | Subsidiary Company | 2018 | California, United States | 10-50 | www.qedtx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. …See details»
QED Therapeutics Information - RocketReach
Qedtx.com; 2 650726XXXX; 925876XXXX; View Similar People. Related Companies Simplee. 13 $14m Cognoa. 49 $9.9m Eiger BioPharmaceuticals. 28 $11.2m EW Healthcare Partners. 30 …See details»
QED Therapeutics – The Chandler Project
QED Therapeutics is a biotechnology company dedicated to developing innovative treatments for rare genetic diseases, including achondroplasia and hypochondroplasia. Their focus is on …See details»
QED Therapeutics - Overview, News & Similar companies
May 27, 2021 www.qedtx.com. Revenue <$5 Million. Industry Business Services General Business Services . Recent News & Media. Achondroplasia Treatment Drug Market to …See details»
QED Therapeutics Staff Directory & Email Format - ContactOut
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in …See details»
QED Therapeutics - Contact Details and Employee Directory
Explore QED Therapeutics at (qedtx.com) based in United States. Discover its industry, revenue, and key employees. Find data for similar companies as well. Why Adapt? Platform. …See details»
Stay Informed | Contact Us | QED Therapeutics - qedtx.com
By selecting proceed, you will leave QEDtx.com and be directed to an external website. Links to all outside sites are provided as a reference for our visitors. QED does not endorse and is not …See details»
QED Therapeutics - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and …See details»
Skeletal Dysplasia Community | Support Groups and Resources
There are many advocacy organizations and hypochondroplasia and achondroplasia support groups that offer vital connections, resources, and a sense of community for those living with …See details»
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn …
May 28, 2021 BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the …See details»
QED Therapeutics - Overview and Employees Official Email
How do Emails and Phone Numbers of QED Therapeutics Help in Bringing Leads?. After viewing all the QED Therapeutics employees' emails like the emails of the HR Head Email, Managing …See details»
JOB DESCRIPTION - qedtx.com
• Vendor Management. Responsible for collection and preparation of all information needed to facilitate selection, on -boarding and management of CRO and vendors for outsourced …See details»
BridgeBio Pharma’s Affiliate QED Therapeutics & Helsinn Group …
Apr 1, 2021 BridgeBio Pharma, Inc., through its affiliate QED Therapeutics, Inc., and Helsinn Group recently announced a global collaboration and licensing agreement to further develop …See details»
Houston Texas Skyline - QED Therapeutics - qedtx.com
The information provided on this site is intended for United States audiences only. By selecting ENTER you confirm you are a user in the United States.See details»
Achondroplasia Research | PROPEL Clinical Trials Overviews
The PROPEL clinical program is studying a wide range of outcomes related to growth, medical challenges, and quality of life in children and adolescents with achondroplasia.. PROPEL is an …See details»